Lilly to present more than 50 studies at ASCO meeting
INDIANAPOLIS Eli Lilly & Co. will unveil more than 50 studies at the 45th annual meeting of the American Society of Clinical Oncology in Orlando Fla., the drug maker announced Tuesday.
The company said most of the studies it will present at the meeting, which will take place from May 29 to June 2, will deal with its thoracic cancer research, such as the latest research findings on Alimta (pemetrexed) and Gemzar (gemcitabine hydrochloride), as well as the investigational drug enzastaurin. The company will also feature the newest molecules in its portfolio resulting from its acquisition of ImClone Systems.
“ASCO’s theme of ‘Personalizing Cancer Care’ is one to which Lilly has subscribed for many years,” Lilly VP cancer research and global oncology platform leader Richard Gaynor said in a statement. “We are focused on delivering what we call ‘tailored therapies’ – an essential component of personalized medicine – to identify patients who are most likely to respond to therapy, and just as importantly, which patients will not.”
Sanofi-Aventis U.S. acquires rights to leukemia drug
BRIDDGEWATER, N.J. The U.S. subsidiary of French drug maker Sanofi-Aventis has acquired the rights to a drug for treating chronic lymphocytic leukemia, the company announced.
Sanofi-Aventis U.S. said it acquired the drug Oforta (fludarabine phosphate) from biotech company Antisoma. Oforta, a tablet, is approved in the United States for treating B-cell chronic lymphocytic leukemia in adults.
“We are extremely pleased to add Oforta to our existing oncology portfolio and believe it represents an exciting opportunity for Sanofi-Aventis U.S.,” the company’s VP and head of its Oncology Business Unit John Harrington stated. “Sanofi-Aventis is a company committed to identifying and exploring new treatment options for patients facing serious diseases, such as CLL.”
Antisoma licenses certain rights and purchases Oforta from Bayer Schering Pharma. Sanofi-Aventis U.S. will acquire the agreements under the transaction.
McKesson to oversee strategic vaccine reserve
SAN FRANCISCO McKesson Corp. has been tapped by the Centers for Disease Control and Prevention to store and supply the nation’s strategic reserve of 2008-2009 seasonal influenza vaccines.
Under a contract signed with the CDC, McKesson will warehouse and potentially distribute up to 500,000 flu vaccine doses from its specialty distribution centers.
Behind the agency’s choice of McKesson: the company’s ability to handle the special storage and supply-chain requirements of distributing vaccines. The health services and distribution giant also holds the appropriate local, state and federal licenses for safely handling and transporting regulated drug products.
“Outsourced vaccine storage requires a distributor with experience and infrastructure to assure that supply chain systems are stable and secure,” said Philip Bolger, VP and general manager for distribution and physician services at McKesson Specialty Care Solutions. “In addition, McKesson can support the compressed timetable for vaccine distribution across the U.S. and its territories.”
Given their composition and limited shelf life, vaccines require special handling to maintain their viability through the storage and distribution process. “Precise cold chain management is critical to the product being received by the end user in manufacturer-recommended conditions,” the company noted.
Through a previous contract with the CDC, McKesson already supplies vaccines for public-sector needs. Two of its specialty distribution centers are primarily dedicated to that program, which shifted to a centralized distribution model in 2007 and delivers pediatric and adult vaccines to more than 46,000 providers across the United States and its territories.
“The demands of CDC programs require a distributor with experience, flexibility and vision, and we are honored by the CDC’s continued confidence in McKesson to meet these needs,” said Pat Blake, president of McKesson Specialty Care Solutions.